Blood Reviews
Volume 21, Issue 5 , Pages 255-265, September 2007

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma☆

Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905 United States

published online 19 March 2007.

Summary 

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic disorders characterized by monoclonal plasma cell proliferation in the bone marrow in the absence of end-organ damage. Updated diagnostic criteria for these disorders, risk-stratification models to determine prognosis, and the current management of these two entities are discussed in this review.

Keywords: Monoclonal Gammopathy, Smoldering Multiple Myeloma, Prognosis, Treatment

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ SVR has received research support for the conduct of clinical trials at Mayo Clinic from Celgene Corp and Millennium Pharmaceuticals, Ltd. RAK has received consulting fees from Novartis Pharmaceuticals Corp, Celgene Corp, Millennium Pharmaceuticals, Ltd, Aeterna Zentaris Inc, and NeoRx Corp.

PII: S0268-960X(07)00003-3

doi:10.1016/j.blre.2007.01.002

Blood Reviews
Volume 21, Issue 5 , Pages 255-265, September 2007

Article Tools

* Image Usage & Resolution